Recombinant Human Fms-related Tyrosine Kinase 4, 7 Domains, Fc-tagged

• Cat.No.: FLT4-85H
• Product Overview: Recombinant Human Soluble Human Fms-related Tyrosine Kinase 4 fused with the Fc part of human IgG1 produced in baculovirus is a monomeric, glycosylated, polypeptide containing 774 amino acids and having a molecular mass of 260 kDa. The soluble receptor protein contains only the first 7 extracellular domains, which contain all the information necessary for ligand binding. The VEGFR3 Fc Chimera is purified by proprietary chromatographic techniques.

Specification

• Cat. No.: FLT4-85H
• Description: All three VEGF receptors belong to the class III subfamily of receptor tyrosine kinases (RTKs) characterised by the seven immunoglobulin-like loops in the extracellular domain. The expression of VEGFR-1 to -3 is almost exclusively restricted to hematopoietic precursor cells, vascular and lymphatic endothelial cells and to the monocyte/macrophage lineage. They play key roles in vasculogenesis, hematopoiesis, angiogenesis and lymphangiogenesis. The FLT-4 cDNA encodes a 1298 amino acid (aa) residue precursor protein with a 23 aa residue signal peptide. Mature VEGFR-3/FLT-4 is composed of a 751 aa residue extracellular domain, a 22 aa transmembrane domain and a 482 aa residue cytoplasmic domain. Both VEGF family members VEGF-C and VEGF-D have been shown to bind and activate VEGFR-3/FLT-4. The Flt-4 gene is widely expressed in the early embryo but becomes restricted to the lymphatic endothelial a latter stages of development. It is important for lymphangiogenesis.
• Source: Insect Cells
• Physical Appearance: Sterile Filtered White lyophilized (freeze-dried) powder.
• Purity: Greater than 90.0% as determined by: (a) Analysis by RP-HPLC. (b) Analysis by SDS-PAGE.
• Formulation: FLT-4 Fc Chimera was lyophilized from a concentrated (1 mg/ml) sterile solution containing no additives.
• Solubility: It is recommended to reconstitute the lyophilized FLT4 Fc Chimera in sterile water not less than 100 µg/ml, which can then be further diluted to other aqueous solutions.
• Biological Activity: Measured by its ability to bind recombinant rat VEGF-C in a functional solid phase binding assay. Immobilised recombinant human VEGFR-3/FLT-4 at 5 µg/ml can bind recombinant rat VEGF-C in a linear range of 8-500 ng/ml.
• Storage: Lyophilized sVEGFR3 although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution VEGFR-3 should be stored at 4°Cbetween 2-7 days and for future use below -18°C. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA). Please prevent freeze-thaw cycles.

Gene Information

• Gene Name: FLT4 fms-related tyrosine kinase 4 [ Homo sapiens ]
• Synonyms: FLT4; fms-related tyrosine kinase 4; PCL; FLT41; LMPH1A; VEGFR3; soluble VEGFR3 variant 1; soluble VEGFR3 variant 2; soluble VEGFR3 variant 3; vascular endothelial growth factor receptor 3; EC 2.7.10.1; 3` partial; Tyrosine-protein kinase receptor FLT4; VEGFR-3
• Gene ID: 2324
• mRNA Refseq: NM_002020
• Protein Refseq: NP_002011
• MIM: 136352
• UniProt ID: P35916
• Chromosome Location: 5q34-q35
• Pathway: Cytokine-cytokine receptor interaction; Focal adhesion; Signaling by VEGF
• Function: ATP binding; growth factor binding; nucleotide binding; receptor activity; transferase activity; vascular endothelial growth factor receptor activity